By Dr Derek Jellinek
25 August 2022, 8:30 AM
Sonic Healthcare (ASX:SHL) FY22 results were above expectations, with COVID testing continuing across all laboratories, helping to expand margins and support double-digit profit growth.
Read more...
By Dr Derek Jellinek
24 August 2022, 9:00 AM
Ansell's (ASX:ANN) FY22 underlying results were in line with guidance but mixed, with lower organic sales and GPM compressing, but higher than expected profit on considerably lower SG&A and tax.
Read more...
By Scott Power
24 August 2022, 7:00 AM
Nanosonics (ASX:NAN) posted an in-line FY22 result, assisted by lower operating costs and a tax benefit.
Read more...
By Dr Derek Jellinek
22 August 2022, 8:25 AM
FY22 results tracked our estimates and guidance, albeit below consensus, with strong sales growth, GMs at pre-COVID levels and double-digit underlying profit.
Read more...
By Iain Wilkie
18 August 2022, 4:00 PM
Pro Medicus (ASX:PME) recorded another year of strong growth across all metrics with the key highlight being further EBIT margin expansion to 67% well above expectations, highlighting the operating leverage of the business.
Read more...
By Dr Derek Jellinek
18 August 2022, 8:30 AM
CSL Ltd (ASX:CSL) FY22 results were slightly softer than expected, albeit in line with management’s assumptions, with net profit falling 6% in cc on 3% revenue growth.
Read more...
By Dr Derek Jellinek
15 August 2022, 9:05 AM
4Q was ahead of expectations, with strong demand, Philips' device recall gains and price rises helping expand GMs but operating margins flat on higher opex. View our full analysis.
Read more...
By Iain Wilkie
17 June 2022, 9:00 AM
Since our last report (17 March), the losses across our basket of 185 ASX listed healthcare stocks have continued to accelerate, with an average loss of 23.5%.
Read more...
By Dr Derek Jellinek
17 June 2022, 8:30 AM
ResMed Inc (ASX:RMD) is acquiring Medifox Dan, a German-based, privately-held, out-of-hospital software provider, for cUS$1bn, funded via existing cash and debt.
Read more...
By Scott Power
26 May 2022, 9:30 AM
Nanosonics (ASX:NAN) provided a solid trading update with 3Q sales and installed base growing in line with 2Q, the company noted it anticipates FY22 revenue will be in line with consensus.
Read more...